Journal of pediatric ophthalmology and strabismus · 2026
Characterizing the Treatment Courses of Ranibizumab and Panretinal Photocoagulation for Retinopathy of Prematurity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vought Victoria, Vought Rita, Crane Alexander B, Guo Suqin, Bhagat Neelakshi, Zarbin Marco A, Wagner Rudolph S
Аннотация
PURPOSE: This study characterizes the treatment course and outcomes of infants with retinopathy of prematurity (ROP) treated with ranibizumab, panretinal photo-coagulation (PRP), or combined therapy.
METHODS: This retrospective chart review analyzed electronic health record data of infants treated for ROP between 2016 and 2024 at a single academic center.
RESULTS: Thirty-seven infants (72 eyes) were analyzed (59.05% male, average 24.7 ± 1.4 weeks). At first treatment, most eyes were zone II, stage 3+ (59.7%). All eyes had plus disease except six treated for persistent avascular retina. PRP was administered as initial therapy for 30 (41.7%) eyes and ranibizumab for 42 (58.3%). Thirty-five eyes (48.6%) underwent only one treatment of either PRP (26 eyes; 36.1%) or ranibizumab (9 eyes; 12.5%). A second treatment consisting of ranibizumab was administered in 4 (13.3%) of 30 eyes treated with PRP and 21 (50%) of 42 eyes injected with ranibizumab. Eight eyes (11.1%) had three treatments: two ranibizumab injections followed by PRP. Four eyes (5.6%) had four treatments: three ranibizumab injections followed by PRP. ROP reactivation occurred in 14 (19.4%) eyes that all received ranibizumab injection initially (mean 50.6 ± 16.7 days after most recent injection). Final outcomes included PRP for persistent avascular retina in 22 (30.6%) eyes, unknown final outcomes due to lost follow-up for 16 (22.2%), documented resolution in 33 (45.8%), and scleral buckling for a peripheral retinal detachment (stage 4a) for one (1.4%).
CONCLUSIONS: Ranibizumab was initiated at a younger age with higher retreatment and reactivation events compared to PRP, underscoring variability in real-world ROP treatment patterns and outcomes.
METHODS: This retrospective chart review analyzed electronic health record data of infants treated for ROP between 2016 and 2024 at a single academic center.
RESULTS: Thirty-seven infants (72 eyes) were analyzed (59.05% male, average 24.7 ± 1.4 weeks). At first treatment, most eyes were zone II, stage 3+ (59.7%). All eyes had plus disease except six treated for persistent avascular retina. PRP was administered as initial therapy for 30 (41.7%) eyes and ranibizumab for 42 (58.3%). Thirty-five eyes (48.6%) underwent only one treatment of either PRP (26 eyes; 36.1%) or ranibizumab (9 eyes; 12.5%). A second treatment consisting of ranibizumab was administered in 4 (13.3%) of 30 eyes treated with PRP and 21 (50%) of 42 eyes injected with ranibizumab. Eight eyes (11.1%) had three treatments: two ranibizumab injections followed by PRP. Four eyes (5.6%) had four treatments: three ranibizumab injections followed by PRP. ROP reactivation occurred in 14 (19.4%) eyes that all received ranibizumab injection initially (mean 50.6 ± 16.7 days after most recent injection). Final outcomes included PRP for persistent avascular retina in 22 (30.6%) eyes, unknown final outcomes due to lost follow-up for 16 (22.2%), documented resolution in 33 (45.8%), and scleral buckling for a peripheral retinal detachment (stage 4a) for one (1.4%).
CONCLUSIONS: Ranibizumab was initiated at a younger age with higher retreatment and reactivation events compared to PRP, underscoring variability in real-world ROP treatment patterns and outcomes.